$ATAI
ATAI Life Sciences NV

2023 Q3 Form 10-Q Financial Statement

#000095017023041345 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $87.00K $172.0K
YoY Change 262.5% 1.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.63M $16.56M
YoY Change -29.81% -3.85%
% of Gross Profit
Research & Development $13.29M $15.48M
YoY Change -30.16% -13.78%
% of Gross Profit
Depreciation & Amortization $80.00K $79.00K
YoY Change 122.22% 315.79%
% of Gross Profit
Operating Expenses $26.92M $32.03M
YoY Change -29.98% -9.83%
Operating Profit -$26.83M -$31.86M
YoY Change -30.16% -9.88%
Interest Expense $686.0K $658.0K
YoY Change -85.14% -86.84%
% of Operating Profit
Other Income/Expense, Net $70.68M $204.0K
YoY Change 1236.38% -95.52%
Pretax Income $43.85M -$31.66M
YoY Change -232.33% 2.77%
Income Tax $200.0K $185.0K
% Of Pretax Income 0.46%
Net Earnings $44.24M -$33.04M
YoY Change -230.56% -9.77%
Net Earnings / Revenue 50855.17% -19210.47%
Basic Earnings Per Share $0.28 -$0.21
Diluted Earnings Per Share $0.25 -$0.21
COMMON SHARES
Basic Shares Outstanding 166.0M 166.0M
Diluted Shares Outstanding 177.6M 155.8M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $209.0M $227.5M
YoY Change -31.26% -27.2%
Cash & Equivalents $76.50M $141.1M
Short-Term Investments $132.5M $86.40M
Other Short-Term Assets $638.0K $1.435M
YoY Change -53.33% 8.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $215.8M $242.8M
YoY Change -32.02% -24.98%
LONG-TERM ASSETS
Property, Plant & Equipment $992.0K $1.043M
YoY Change 36.26% 244.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0%
Other Assets $3.107M $3.267M
YoY Change -64.44% -56.96%
Total Long-Term Assets $92.40M $10.83M
YoY Change 267.89% -57.26%
TOTAL ASSETS
Total Short-Term Assets $215.8M $242.8M
Total Long-Term Assets $92.40M $10.83M
Total Assets $308.2M $253.6M
YoY Change -10.03% -27.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.506M $3.859M
YoY Change 56.82% 40.94%
Accrued Expenses $13.01M $12.86M
YoY Change -41.25% -32.03%
Deferred Revenue
YoY Change
Short-Term Debt $132.5M $86.40M
YoY Change -17.96% -62.17%
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $19.70M $17.93M
YoY Change -24.0% -18.36%
LONG-TERM LIABILITIES
Long-Term Debt $15.40M $15.29M
YoY Change 2.66% 2369.79%
Other Long-Term Liabilities $2.736M $2.807M
YoY Change -25.95% -28.03%
Total Long-Term Liabilities $2.736M $2.807M
YoY Change -25.95% -28.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.70M $17.93M
Total Long-Term Liabilities $2.736M $2.807M
Total Liabilities $39.71M $37.96M
YoY Change -14.64% 31.73%
SHAREHOLDERS EQUITY
Retained Earnings -$532.6M -$576.9M
YoY Change 14.49% 33.76%
Common Stock $18.57M $18.57M
YoY Change 0.09% 2.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $266.3M $212.6M
YoY Change
Total Liabilities & Shareholders Equity $308.2M $253.6M
YoY Change -10.03% -27.32%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $44.24M -$33.04M
YoY Change -230.56% -9.77%
Depreciation, Depletion And Amortization $80.00K $79.00K
YoY Change 122.22% 315.79%
Cash From Operating Activities -$18.43M -$22.61M
YoY Change -34.28% 3.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $128.0K
YoY Change -100.0% -159.26%
Acquisitions
YoY Change
Other Investing Activities -$46.48M -$21.88M
YoY Change -169.81% 21.55%
Cash From Investing Activities -$46.48M -$22.01M
YoY Change -170.37% 20.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -100.0K
YoY Change -100.0% -105.57%
NET CHANGE
Cash From Operating Activities -18.43M -22.61M
Cash From Investing Activities -46.48M -22.01M
Cash From Financing Activities 0.000 -100.0K
Net Change In Cash -64.91M -44.72M
YoY Change -212.33% 16.6%
FREE CASH FLOW
Cash From Operating Activities -$18.43M -$22.61M
Capital Expenditures $0.00 $128.0K
Free Cash Flow -$18.43M -$22.74M
YoY Change -33.02% 4.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001840904
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 atai Share Subscription Receivable
ShareSubscriptionReceivable
-24000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20818000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21702000
us-gaap Revenues
Revenues
209000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40493
dei Entity Registrant Name
EntityRegistrantName
ATAI Life Sciences N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
ATAI Life Sciences N.V.
dei Entity Address Address Line2
EntityAddressAddressLine2
Wallstraße 16, 10179
dei Entity Address City Or Town
EntityAddressCityOrTown
Berlin
dei Entity Address Country
EntityAddressCountry
DE
dei City Area Code
CityAreaCode
49 89
dei Local Phone Number
LocalPhoneNumber
2153 9035
dei Security12b Title
Security12bTitle
Common shares, par value €0.10 per share
dei Trading Symbol
TradingSymbol
ATAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
166010476
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141090000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190613000
CY2023Q2 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
86402000
CY2022Q4 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
82496000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6257000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
9021000
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0
CY2023Q2 us-gaap Assets Current
AssetsCurrent
242770000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
287145000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1043000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
928000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1367000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-576891000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510188000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212550000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260740000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q2 us-gaap Other Long Term Investments
OtherLongTermInvestments
3991000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
CY2023Q2 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
1157000
CY2022Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
7262000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3267000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3125000
CY2023Q2 us-gaap Assets
Assets
253595000
CY2022Q4 us-gaap Assets
Assets
305441000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3859000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2399000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12855000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
322000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
890000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17926000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19897000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
842000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
953000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1095000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q2 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
420000
CY2022Q4 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
415000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
14868000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2807000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3664000
CY2023Q2 us-gaap Liabilities
Liabilities
37958000
CY2022Q4 us-gaap Liabilities
Liabilities
39675000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166010476
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166010476
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
165935914
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
165935914
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18571000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18562000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
791688000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
774092000
CY2023Q2 atai Share Subscription Receivable
ShareSubscriptionReceivable
0
CY2023Q2 us-gaap Minority Interest
MinorityInterest
3087000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
215637000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253595000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305441000
CY2023Q2 us-gaap Revenues
Revenues
172000
CY2022Q2 us-gaap Revenues
Revenues
170000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
185000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
351000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1928000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
209000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
204000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4551000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
263000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6072000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31658000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-30806000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-64814000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-62727000
us-gaap Revenues
Revenues
170000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15476000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17949000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
34757000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
33409000
CY2023Q2 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
CY2022Q2 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
357000
atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
357000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16558000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17221000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30529000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35203000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
32034000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
35527000
us-gaap Operating Expenses
OperatingExpenses
65286000
us-gaap Operating Expenses
OperatingExpenses
68969000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31862000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35357000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65077000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68799000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
303000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
117000
us-gaap Investment Income Interest
InvestmentIncomeInterest
579000
us-gaap Investment Income Interest
InvestmentIncomeInterest
215000
CY2023Q2 us-gaap Interest Expense
InterestExpense
658000
CY2022Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1280000
us-gaap Interest Expense
InterestExpense
0
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-76000
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-95000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-111000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-95000
CY2023Q2 atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
0
CY2022Q2 atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
53000
atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
0
atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
53000
CY2023Q2 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
526000
CY2022Q2 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-584000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
1490000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-1324000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4882000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-846000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7045000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-6652000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2961000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-12248000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-33771000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-37509000
us-gaap Profit Loss
ProfitLoss
-68126000
us-gaap Profit Loss
ProfitLoss
-75067000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-729000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-891000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1948000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1580000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33042000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-36618000
us-gaap Net Income Loss
NetIncomeLoss
-66178000
us-gaap Net Income Loss
NetIncomeLoss
-73487000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155792490
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153971202
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153971202
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155793323
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793323
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153751456
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153751456
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-33771000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-37509000
us-gaap Profit Loss
ProfitLoss
-68126000
us-gaap Profit Loss
ProfitLoss
-75067000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8482000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
884000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12855000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33766000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-45991000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-67242000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-87922000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
729000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
891000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1948000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1580000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
1000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
30000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
9000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
19000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-728000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-861000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1939000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1561000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33038000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45130000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65303000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86361000
CY2022Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181000
CY2023Q1 atai Settlement Of Issuance Of Common Shares Value
SettlementOfIssuanceOfCommonSharesValue
24000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8662000
CY2023Q1 atai Adjustment To Accumulated Deficit Pursuant To Adoption Of Asu201613
AdjustmentToAccumulatedDeficitPursuantToAdoptionOfAsu201613
-526000
CY2023Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
887000
CY2023Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-34354000
CY2023Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
240640000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8762000
CY2023Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
6000
CY2023Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-33771000
CY2023Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
215637000
CY2021Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
385959000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
132000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10208000
CY2022Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4384000
CY2022Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37558000
CY2022Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
354357000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1140000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
CY2022Q2 atai Issuance Of Subsidiary Preferred Shares
IssuanceOfSubsidiaryPreferredShares
600000
CY2022Q2 atai Issuance Of Subsidiary Common Shares
IssuanceOfSubsidiaryCommonShares
357000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9511000
CY2022Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-8452000
CY2022Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37509000
CY2022Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
320122000
us-gaap Profit Loss
ProfitLoss
-68126000
us-gaap Profit Loss
ProfitLoss
-75067000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79000
atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
218000
atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
173000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-111000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-95000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
1490000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-1324000
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
0
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-53000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
2961000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
12242000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
357000
us-gaap Share Based Compensation
ShareBasedCompensation
17424000
us-gaap Share Based Compensation
ShareBasedCompensation
19720000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-835000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
4966000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-244000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-134000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7798000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
939000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1403000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2591000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4710000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2328000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43725000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45917000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
251000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
172000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
320000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
100000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
39617000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
229678000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37201000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5987000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232950000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
249000
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
0
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
600000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1077000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
100000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1926000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1193000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49523000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-278134000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190613000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362266000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141090000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84132000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1402000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Interest Paid Net
InterestPaidNet
933000
us-gaap Interest Paid Net
InterestPaidNet
0
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
487000
atai Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement
IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement
0
atai Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement
IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement
357000
us-gaap Nature Of Operations
NatureOfOperations
<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Or</span><span id="notes"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">576.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of June 30, 2023 will be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141100000
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
86400000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-576900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”) and noncontrolling interests recognized in acquisitions, the valuation of share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2023Q2 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-729000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
147322000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
154830000
CY2023Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2022Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2200000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000000.0
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q1 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-1219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-8000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3815000
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-1000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
3087000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
9051000
CY2022Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-689000
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-11000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8351000
CY2022Q2 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
957000
CY2022Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-891000
CY2022Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-30000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
8447000
CY2023Q2 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
3900000
CY2022Q4 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
6800000
CY2022Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
7200000
CY2023Q2 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q2 us-gaap Other Long Term Investments
OtherLongTermInvestments
3991000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
atai Equity Method Investment Shares Transaction Date
EquityMethodInvestmentSharesTransactionDate
2026-12-31
us-gaap Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
9600000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2300000
CY2022 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0
CY2021Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3000000.0
CY2023Q2 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
200000
CY2022Q2 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
100000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
400000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
200000
CY2023Q2 us-gaap Loans And Leases Receivable Net Reported Amount
LoansAndLeasesReceivableNetReportedAmount
8500000
CY2022Q4 us-gaap Loans And Leases Receivable Net Reported Amount
LoansAndLeasesReceivableNetReportedAmount
5500000
CY2023Q2 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2022Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2023Q2 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2022Q4 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
41000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2034000
CY2023Q2 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
3019000
CY2022Q4 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
4626000
CY2023Q2 us-gaap Prepaid Taxes
PrepaidTaxes
1762000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
5631000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1435000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1745000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6257000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3023000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3566000
CY2023Q2 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4886000
CY2022Q4 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
5550000
CY2023Q2 atai Accrued Restructuring Costs
AccruedRestructuringCosts
91000
CY2022Q4 atai Accrued Restructuring Costs
AccruedRestructuringCosts
0
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3137000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5260000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
808000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2224000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
910000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
706000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12855000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.125
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1367000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
322000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1095000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
77000
us-gaap Operating Lease Cost
OperatingLeaseCost
280000
us-gaap Operating Lease Cost
OperatingLeaseCost
124000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
249000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
410000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
366000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
366000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
366000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
122000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
1879000
CY2023Q2 us-gaap Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
462000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1417000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
187000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
120000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
487000
CY2023Q2 us-gaap Convertible Debt
ConvertibleDebt
420000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
415000
CY2023Q2 us-gaap Loans Held For Sale Maturity Date
LoansHeldForSaleMaturityDate
2026-08-01
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
175000000.0
CY2023Q2 atai Prime Rate Percent
PrimeRatePercent
0.0455
CY2023Q2 atai Accrued Interest Payable
AccruedInterestPayable
0.0855
CY2022Q3 atai Borrowing Amount Percentage
BorrowingAmountPercentage
0.33
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2023Q2 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2022Q4 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-240000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-274000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-99000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-113000
CY2023Q2 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-835000
CY2022Q4 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-952000
CY2023Q2 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14868000
CY2022Q4 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14702000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
14868000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20843522
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6500000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
185000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
351000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-33771000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-37509000
us-gaap Profit Loss
ProfitLoss
-68126000
us-gaap Profit Loss
ProfitLoss
-75067000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-729000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-891000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1948000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1580000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33042000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33042000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36618000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36618000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66178000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-66178000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73487000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-73487000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155792490
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153971202
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153971202
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155793323
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793323
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153751456
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153751456
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58187977
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
51019091
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
300000
atai Related Party Reservation Rate Of Common Shares For Ipo
RelatedPartyReservationRateOfCommonSharesForIpo
0.27
CY2023Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
CY2022Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
300000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
200000
CY2023Q1 atai Percentage Of Restructed Workforce
PercentageOfRestructedWorkforce
0.30
us-gaap Restructuring Costs
RestructuringCosts
3200000
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
100000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
us-gaap Restructuring Costs
RestructuringCosts
3194000
atai Non Cash Impact Of Stock Based Compensation
NonCashImpactOfStockBasedCompensation
195000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2908000
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
91000

Files In Submission

Name View Source Status
0000950170-23-041345-index-headers.html Edgar Link pending
0000950170-23-041345-index.html Edgar Link pending
0000950170-23-041345.txt Edgar Link pending
0000950170-23-041345-xbrl.zip Edgar Link pending
atai-20230630.htm Edgar Link pending
atai-20230630.xsd Edgar Link pending
atai-ex31_1.htm Edgar Link pending
atai-ex31_2.htm Edgar Link pending
atai-ex32_1.htm Edgar Link pending
atai-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img105941588_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
atai-20230630_cal.xml Edgar Link unprocessable
atai-20230630_def.xml Edgar Link unprocessable
atai-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atai-20230630_pre.xml Edgar Link unprocessable
atai-20230630_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending